No Data
No Data
Immuneering Is Maintained at Buy by Chardan Capital
Express News | 5Needham Reiterates Buy on Immuneering, Maintains $15 Price Target
Immuneering Analyst Ratings
Express News | Immuneering Corp : Chardan Capital Markets Cuts Target Price to $12 From $16
Buy Rating on Immuneering: Fast-Track FDA Designation and Promising Clinical Trials Underpin Positive Outlook
Express News | Immuneering Corp - Expects Its Cash Runway to Be Sufficient to Fund Operations Into Second Half of 2025
No Data